Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I hope we can get things moving before the process below take place.
Yes, and it is important to this message board
Biden Proposes 44.6% Capital Gains Tax- Highest in U.S. History
Thanks - Don't know how I missed that, I'm been here for almost 10 years maybe more who the heck knows. And for the last 15 months every day.
Every minute well almost.
Even added today and will again.
I will pass on the entire press release to the family.
Thanks
Smitty - I would appreciate more information on the PIP.
I know someone at St Jude's right now.
Where can I find out more information?
Can they contact Dr. A in England? Kings College
I appreciate your help - I will talk to this person in a few days.
Gary, And this is one of the main reasons why DCVAX is being attacked.
Big Pharma Business does not like us.
While it's clear that if CAR-T is the only choice to cure a specific cancer it should be used even if it means routinely monitoring the patient the rest of their life for other cancers it may cause. On the other hand, if DCVax-L and Direct prove to be of equal or greater benefit, in time CAR-T might not be used at all.
Agree, I would take the 7 to 8 dollar buyout also.
Then follow the company that will make billions on our technology.
But I would like a split between shares and cash and if all shares better yet!
Then I can decide how much taxes I will end up paying.
That 7 dollar buyout would blossom to over 30+ dollars with the new company.
And that may be low!
Don't Make Me Leak (Hello Alice)
I wonder if he went to Germany? If you page down on all the updates, he mentions Germany.
No issues here, 50k
Filled in minutes
I liked the idea someone had many months ago.
Give out a .01 penny dividend with the first month's revenue after approval.
I think all shares have to be accounted for.
But people here know much more than myself.
Don't Make Me Leak - Alice
Looking at the links page, isn't an April update a little late?
https://www.gov.uk/government/publications/marketing-authorisations-granted-in-2024#full-publication-update-history
Maybe this Thursday
25 March 2024
Marketing authorisations granted 1 March to 14 March 2024 have been added.
7 March 2024
Added Marketing authorisations granted 15 to 29 February 2024
21 February 2024
Marketing authorizations granted from 1 to 14 February 2024 have been added.
8 February 2024
First published.
Can someone please post Dr. Keyoumars Ashkan Secretary contact.
Thanks in advance.
Always seems like I know some one that can use this treatment.
But I find it hard to approach this person and provide the details.
Not only a major positive impact in the overall cure for cancer just think what this vaccine does to society.
Just thinking of everyone living longer.
Social Security - Pensions - Housing -Food - Energy
And guess what? I'm all for it, the next generation of health care coming very soon!
Turn the Page, we are in the home stretch.
We are blessed to be a early part of this disruptive vaccine.
Don't Make Me Leak - Alice LOL
Let's start the Party
Well we could just discuss the same thing over and over and over again.
Fact is the King received treatment in February and still has his hair.
No big deal , Lets discuss test results again LOL
or maybe why our Phase 3 testing was halted.
or like today what the crap Linda did some 10+ years ago
Have a great Day, I'm looking for a great month of April.
King Charles seen after Easter Church, Still not losing his hair.
Chemo? or just DCVAX without Chemo
Just something new to think about
I don't think the King and Princess would take Chemo if they are going to go our route to DCVAX.
Maybe or Maybe Not
But my good investors in England - keep an eye on the news and when they film them notice if they are loosing their hair.
Sounds Lousy but there it is!
Don't Make Me Leak - Hello Alice
I hope this company has contacted the proper people, if they did not I have no words that can
justify their action.
Let's hope and pray that this company has offered their services
Tryn2 - It is possible that a merger can be developed with a new stock symbol (company) therefore all the outstanding shares would be adjusted into the new
Company. Could this be a way to adjust the outstanding shares?
Doc Logic - I hope we will get all shares, and then I can decide how many I can sell keeping Taxes in mind.
Also if income rises over certain amounts, the cost of medicare increases.
Why give the government part of my success, make them wait or my Children can inherit my shares with a new base price?
My response indicates that I have many shares, and more than a lifetime of earnings to come out of this stock.
Keep the taxes low
Inquirig Numbers - If my count is correct that would be 430 post just for the month of March - 19 days
Now for a Pivot Table for a count per day.
Yes, Linda is playing a great game of Poker and holding a Royal Flush.
Don't Make Me Leak! -- Hello Alice
Smokey -You never know what is going on at UCLA. (New combo studies??)
We don't know or hear everything, that's for sure with the company so silent.
This side of the Atlantic!
I still would email Sue.
Market Makers throwing up many 100 sh block trades.
Indicating: I NEED SHARES!
lol
Merck is ramping up its R&D efforts to introduce a new version of the blockbuster cancer drug Keytruda, as the pharma giant faces loss of market exclusivity for its top revenue generator later this decade.
The intravenously delivered anti-PD-1 therapy is approved for nearly 40 indications in the U.S., and it accounted for more than 40% of the company’s total sales in 2023, adding $25.0B to the top line.
According to an update posted in a federal register this week, the company has increased the number of study sites for a Phase 2 trial designed to test subcutaneous Keytruda in multiple tumors. That trial, targeted at more than 100 patients, is expected to be completed in 2026.
The recent update shows that its enrollment has improved to more than 370 patients last month. The Japan-based trial is expected to be completed in 2028.
The new formulation “is an innovation that is going to be demanded and is being demanded by the field,” Merck (MRK) research chief Dean Li said during the company’s recent earnings call.
Hope England is during their review, Quickly LOL
This is out there, but I think we merge with Advent, then down the road franchise or sell the company.
The number of shares will drop.
Given the age of our management that someone brought up!
After this battle, they must enjoy their retirement with what they have achieved here.
Just my guessing
Moderna is down 4% thinking their cancer vaccine is not as good as their competitors!
HSBC cuts them down
Maybe some dog info here - have to go until later
https://archive.vcstar.com/lifestyle/familys-dog-a-cancer-care-guinea-pig-ep-373302876-352494381.html/
Doc, I thought everyone forgot about the dogs!
If my memory is correct they cured the dog of cancer and then tried to give the cancer back to the dog.
The Cancer never showed up!
I could be wrong but that is how I remember the story!
Didn't this news \ story come during a presentation?
I agree, the beautiful thing about this entire journey is anyone interested with
Purchasing this jewel does not give one Dam what AF thinks.
No matter what he says or when he says it!
Don't make Me leak (Alice)
Yes, I agree - Great Poker play by Linda Powers
As far as a buyout price? I would agree with any price that Linda agrees.
Even if it's a bit low, the purchasing company will skyrocket!
I believe most people here will be found on their message boards.
Why not?
DCVAX is to the Medical world as AI is to the Technology World.
The Bashers' Goal is to bury the informative posts!
When Judges were changed the fix was in, Chicago Style
Been here a long time but I can't remember what Eden is all about.
Help? Can someone explain or list the message that explains it.
Interestingly, every time this message board brings the light to some outside presentation or article they Update or hide the original display.
Be it an article or some presentation that a section is edited out.
To the people on the message board, thank you, and keep up the great work!!!
What did I miss
The application has been submitted - It's out of their hands!
But Keep trying - Maybe a Big maybe someone will listen to your poop
wow, typo - everyone knew where I was going with that!
Funny - wishful thinking
We all know that Keytruda Patents expire in 2024. But If BP Picks up DCVAX they will need - let's say 2 years to get
Additional Cancer Treatments passed the FDA.
Guessing here: Setup Testing at Hospitals, Getting docs setup, Setup of Vaccine if needed,
Phase 1 - Phase 2 - Phase 3 --- Application submitted and then a wait -- ( Most likely shorter than ours because of Politics)
So they don't have time to burn.
They don't even have access to DCVAX yet!
And time is ticking away (Science waits for no one) - Not even us LOLOLOL
Most here are thinking that DCVAX will not be utilized for the King.
Saying no way, how would it look if we get approval in England within the first half of the year and
it was never presented to his Doctors? Especially with the results that DCVAX will produce.
I have to believe that DCVAX was in the discussions one way or another.
Now the other side, if it's not been presented to the doctors, does this place our application back many months because we held back
the Data from the King's Doctors? Would not look good
Just throwing this out
King Charles has Cancer
Now is NWBO's Time
Let's go
He cannot come out with the Highest price that he would accept!
Think Car salesman - Negotiations
I place my trust in Linda Powers!
Deal-hungry Merck plans more phase 3 launches than in 2023
Davis reiterated that Merck is interested in deals between $1 billion and $15 billion, with the $10 billion-plus range being the sweet spot.
All these moves are part of Merck’s larger diversification strategy to assuage investor concerns about Keytruda’s 2028 patent expiration.
“We do continue to believe we need more and we will continue to prioritize business development,” Davis said on the Thursday earnings call.
Recent acquisitions and partnerships contributed to Merck’s ballooning R&D spend in 2023, which exceeded a whopping $30 billion in GAAP expenses.
scroll down
https://www.fiercebiotech.com/biotech/merck-plans-more-phase-3-launches-2023-while-voracious-bd-appetite-remains
The monies that can be reinvested into the stock that takes us over and other companies
Will make up any difference in a higher take-out price!
Also, easy to think we will get many new press releases from the new company.
In addition to a bankroll to get us to other cancer treatments.